David P. Richman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David P. Richman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Mark A. Agius
Department of Neurology, Center for Neuroscience, University of California, Davis, California
4 shared publications- Mark A. Agius
Department of Neurology, University of California at Davis, Davis, California 95616, USA
3 shared publications Ricardo A. Maselli
Department of Neurology, Center for Neuroscience, University of California, Davis, California
3 shared publicationsJoachim Schnier
Department of Neurology, Center for Neuroscience, University of California, Davis, California
2 shared publicationsKayoko Nishi
Department of Neurology, Center for Neuroscience, University of California, Davis, California
2 shared publications- Michael Ferns
Department of Physiology and Membrane Biology, University of California Davis
2 shared publications
Latest Publications
- Open Access
- 8 May 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 707
Muscle-Specific Kinase Myasthenia Gravis
Thirty to fifty percent of patients with acetylcholine receptor (AChR) antibody (Ab)-negative myasthenia gravis (MG) have Abs to muscle specific kinase (MuSK) and are referred to as having MuSK-MG. MuSK is a 100 kD single-pass post-synaptic transmembrane receptor tyrosine kinase crucial to the development and maintenance of the neuromuscular junction. The Abs in MuSK-MG are predominantly of the IgG4 immunoglobulin subclass. MuSK-MG differs from AChR-MG, in exhibiting more focal muscle involvement, including neck, shoulder, facial and bulbar-innervated muscles, as well as wasting of the involved muscles. MuSK-MG is highly associated with the HLA DR14-DQ5 haplotype and occurs predominantly in females with onset in the fourth decade of life. Some of the standard treatments of AChR-MG have been found to have limited effectiveness in MuSK-MG, including thymectomy and cholinesterase inhibitors. Therefore, current treatment involves immunosuppression, primarily by corticosteroids. In addition, patients respond especially well to B cell depletion agents, e.g., rituximab, with long-term remissions. Future treatments will likely derive from the ongoing analysis of the pathogenic mechanisms underlying this disease, including histologic and physiologic studies of the neuromuscular junction in patients as well as information derived from the development and study of animal models of the disease.
- 8 May 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 707
Open AccessMuscle-Specific Kinase Myasthenia Gravis
Thirty to fifty percent of patients with acetylcholine receptor (AChR) antibody (Ab)-negative myasthenia gravis (MG) have Abs to muscle specific kinase (MuSK) and are referred to as having MuSK-MG. MuSK is a 100 kD single-pass post-synaptic transmembrane receptor tyrosine kinase crucial to the development and maintenance of the neuromuscular junction. The Abs in MuSK-MG are predominantly of the IgG4 immunoglobulin subclass. MuSK-MG differs from AChR-MG, in exhibiting more focal muscle involvement, including neck, shoulder, facial and bulbar-innervated muscles, as well as wasting of the involved muscles. MuSK-MG is highly associated with the HLA DR14-DQ5 haplotype and occurs predominantly in females with onset in the fourth decade of life. Some of the standard treatments of AChR-MG have been found to have limited effectiveness in MuSK-MG, including thymectomy and cholinesterase inhibitors. Therefore, current treatment involves immunosuppression, primarily by corticosteroids. In addition, patients respond especially well to B cell depletion agents, e.g., rituximab, with long-term remissions. Future treatments will likely derive from the ongoing analysis of the pathogenic mechanisms underlying this disease, including histologic and physiologic studies of the neuromuscular junction in patients as well as information derived from the development and study of animal models of the disease.
- 18 October 2016
- Published by Wiley in European Journal of Neurology
- Vol. 23 (11) , 1593-1594
Lipoprotein‐like receptor 4 antibodies in myasthenia gravis: pathogenic or protective
Click here to view the accompanying paper in this issue.
- 18 October 2016
- Published by Wiley in European Journal of Neurology
- Vol. 23 (11) , 1593-1594
Lipoprotein‐like receptor 4 antibodies in myasthenia gravis: pathogenic or protective
Click here to view the accompanying paper in this issue.
- 17 December 2012
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1274 (1) , 140-147
Animal models of antimuscle‐specific kinase myasthenia
Antimuscle‐specific kinase (anti‐MuSK) myasthenia (AMM) differs from antiacetylcholine receptor myasthenia gravis in exhibiting more focal muscle involvement (neck, shoulder, facial, and bulbar muscles) with wasting of the involved, primarily axial, muscles. AMM is not associated with thymic hyperplasia and responds poorly to anticholinesterase treatment. Animal models of AMM have been induced in rabbits, mice, and rats by immunization with purified xenogeneic MuSK ectodomain, and by passive transfer of large quantities of purified serum IgG from AMM patients into mice. The models have confirmed the pathogenic role of the MuSK antibodies in AMM and have demonstrated the involvement of both the presynaptic and postsynaptic components of the neuromuscular junction. The observations in this human disease and its animal models demonstrate the role of MuSK not only in the formation of this synapse but also in its maintenance.
- 17 December 2012
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1274 (1) , 140-147
Animal models of antimuscle‐specific kinase myasthenia
Antimuscle‐specific kinase (anti‐MuSK) myasthenia (AMM) differs from antiacetylcholine receptor myasthenia gravis in exhibiting more focal muscle involvement (neck, shoulder, facial, and bulbar muscles) with wasting of the involved, primarily axial, muscles. AMM is not associated with thymic hyperplasia and responds poorly to anticholinesterase treatment. Animal models of AMM have been induced in rabbits, mice, and rats by immunization with purified xenogeneic MuSK ectodomain, and by passive transfer of large quantities of purified serum IgG from AMM patients into mice. The models have confirmed the pathogenic role of the MuSK antibodies in AMM and have demonstrated the involvement of both the presynaptic and postsynaptic components of the neuromuscular junction. The observations in this human disease and its animal models demonstrate the role of MuSK not only in the formation of this synapse but also in its maintenance.
- 12 July 2012
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 14 (4) , 328-337
Dominantly Inherited Myotonia Congenita Resulting from a Mutation That Increases Open Probability of the Muscle Chloride Channel CLC-1
- 12 July 2012
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 14 (4) , 328-337
Dominantly Inherited Myotonia Congenita Resulting from a Mutation That Increases Open Probability of the Muscle Chloride Channel CLC-1
- Open Access
- 1 April 2012
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 69 (4) , 453-460
Acute Severe Animal Model of Anti–Muscle-Specific Kinase Myasthenia
Ninety percent of patients with generalized myasthenia gravis (MG) have pathogenic antibodies (Abs) to the nicotinic acetylcholine receptor (AChR), the neuromuscular junction (NMJ) postsynaptic neurotransmitter receptor. However, in about 5% of cases, AChR Abs are absent but the patients have circulating Abs to a second postsynaptic NMJ protein, muscle-specific kinase (MuSK).1 These patients, which we will refer to as having anti-MuSK myasthenia (AMM), have many clinical similarities to those with AChR Ab–positive MG but tend to differ significantly in having more focal involvement with severe weakness of neck, shoulder, facial, and bulbar muscles, frequently with wasting of these muscles.2-5 In contrast to AChR Ab–positive MG, the pathogenic mechanisms underlying AMM are not well understood. In fact, there has been debate over whether MuSK Abs play a direct role in AMM or simply represent an epiphenomenon.6,7 Our study is aimed at addressing this question and better defining the mechanisms by which such an immune attack may produce the disease.
- 1 April 2012
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 69 (4) , 453-460
Open AccessAcute Severe Animal Model of Anti–Muscle-Specific Kinase Myasthenia
Ninety percent of patients with generalized myasthenia gravis (MG) have pathogenic antibodies (Abs) to the nicotinic acetylcholine receptor (AChR), the neuromuscular junction (NMJ) postsynaptic neurotransmitter receptor. However, in about 5% of cases, AChR Abs are absent but the patients have circulating Abs to a second postsynaptic NMJ protein, muscle-specific kinase (MuSK).1 These patients, which we will refer to as having anti-MuSK myasthenia (AMM), have many clinical similarities to those with AChR Ab–positive MG but tend to differ significantly in having more focal involvement with severe weakness of neck, shoulder, facial, and bulbar muscles, frequently with wasting of these muscles.2-5 In contrast to AChR Ab–positive MG, the pathogenic mechanisms underlying AMM are not well understood. In fact, there has been debate over whether MuSK Abs play a direct role in AMM or simply represent an epiphenomenon.6,7 Our study is aimed at addressing this question and better defining the mechanisms by which such an immune attack may produce the disease.
- Open Access
- 1 April 2012
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 69 (4) , 434-435
Antibodies to Low Density Lipoprotein Receptor-Related Protein 4 in Seronegative Myasthenia Gravis
Myasthenia gravis (MG) is a disorder of the neuromuscular junction (NMJ) characterized by muscle weakness that worsens with effort and improves with rest. The electrodiagnostic correlate is decrementing compound muscle action potential amplitudes to slow rates of repetitive nerve stimulation. Although rare forms of myasthenia result from heritable mutations in individual proteins comprising the NMJ, the congenital myasthenic syndromes,1 the vast majority of cases of MG are autoimmune in origin. For 90% of patients with generalized autoimmune MG (ie, involving more than the ocular muscles), the disorder results from circulating autoantibodies to the nicotinic acetylcholine receptor (AChR), which is the NMJ postsynaptic neurotransmitter receptor. The remaining 10% of patients have been referred to as having seronegative (autoimmune) MG. About a decade ago, Hoch and coworkers2 identified antibodies to a second postsynaptic NMJ membrane protein, muscle-specific kinase (MuSK) present in about 40% of seronegative patients. Subsequent studies3-6 in rodents have provided data supporting a pathogenic role for MuSK antibodies in this subgroup of patients. It is the remaining 60% of seronegative patients (now referred to as patients with double-seronegative MG) who are the subject of the study of antibodies to low density lipoprotein receptor-related protein 4 (LRP4) by Zhang et al7 published in this issue of the Archives.
- 1 April 2012
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 69 (4) , 434-435
Open AccessAntibodies to Low Density Lipoprotein Receptor-Related Protein 4 in Seronegative Myasthenia Gravis
Myasthenia gravis (MG) is a disorder of the neuromuscular junction (NMJ) characterized by muscle weakness that worsens with effort and improves with rest. The electrodiagnostic correlate is decrementing compound muscle action potential amplitudes to slow rates of repetitive nerve stimulation. Although rare forms of myasthenia result from heritable mutations in individual proteins comprising the NMJ, the congenital myasthenic syndromes,1 the vast majority of cases of MG are autoimmune in origin. For 90% of patients with generalized autoimmune MG (ie, involving more than the ocular muscles), the disorder results from circulating autoantibodies to the nicotinic acetylcholine receptor (AChR), which is the NMJ postsynaptic neurotransmitter receptor. The remaining 10% of patients have been referred to as having seronegative (autoimmune) MG. About a decade ago, Hoch and coworkers2 identified antibodies to a second postsynaptic NMJ membrane protein, muscle-specific kinase (MuSK) present in about 40% of seronegative patients. Subsequent studies3-6 in rodents have provided data supporting a pathogenic role for MuSK antibodies in this subgroup of patients. It is the remaining 60% of seronegative patients (now referred to as patients with double-seronegative MG) who are the subject of the study of antibodies to low density lipoprotein receptor-related protein 4 (LRP4) by Zhang et al7 published in this issue of the Archives.
- Open Access
- 1 January 2011
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 7 (4) , 173-183
Treatment of Myasthenia Gravis Based on Its Immunopathogenesis
Kim JY, et al. J Clin Neurol. 2011 Dec;7(4):173-183. http://dx.doi.org/10.3988/jcn.2011.7.4.173
- 1 January 2011
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 7 (4) , 173-183
Open AccessTreatment of Myasthenia Gravis Based on Its Immunopathogenesis
Kim JY, et al. J Clin Neurol. 2011 Dec;7(4):173-183. http://dx.doi.org/10.3988/jcn.2011.7.4.173
- 23 December 2003
- Published by Wolters Kluwer Health in Neurology
- Vol. 61 (12) , 1652-1661
Treatment of autoimmune myasthenia gravis
Autoimmune myasthenia gravis (MG) is associated with antibodies directed against the nicotinic acetylcholine receptor (AChR) in 85% of patients. Other postsynaptic neuromuscular junction antigens are implicated, e.g., muscle-specific receptor tyrosine kinase (MuSK), in a number of the remaining 15% of patients, so-called seronegative MG. The autoimmune attack generally leads to decreased concentrations of the AChR and damage to the structure of the endplate itself. This information has guided the empiric treatment of patients with MG and has suggested new treatment strategies. Whereas the outcome of patients with MG has improved because of more effective symptomatic treatment, including advances in critical care medicine and the use of cholinesterase inhibitors, the greatest advances have come from therapies that directly reduce the autoimmune attack or modify its effects on the AChR and the surrounding endplate. Immune-directed treatment of patients with MG, which is guided by this information and by data from the management of other autoimmune disease, is aimed at inducing an immunologic remission and then maintaining that remission. Remission induction is usually accomplished through the use of high-dose corticosteroids, frequently in conjunction with IV immunoglobulin or plasmapheresis. Maintenance of the remission is usually accomplished by slow tapering of the corticosteroids along with the use of “steroid-sparing” agents, which include azathioprine, thymectomy, and possibly mycophenolate. Therapy usually begins with cholinesterase inhibitors. If necessary, immune-directed treatment is added, beginning with either thymectomy or high-dose corticosteroids. The short-term therapies, i.e., IV immunoglobulin or plasmapheresis, may be effective in the early stages of treatment or later during an exacerbation. Steroid-sparing medications are usually added to facilitate the tapering phase.
- 23 December 2003
- Published by Wolters Kluwer Health in Neurology
- Vol. 61 (12) , 1652-1661
Treatment of autoimmune myasthenia gravis
Autoimmune myasthenia gravis (MG) is associated with antibodies directed against the nicotinic acetylcholine receptor (AChR) in 85% of patients. Other postsynaptic neuromuscular junction antigens are implicated, e.g., muscle-specific receptor tyrosine kinase (MuSK), in a number of the remaining 15% of patients, so-called seronegative MG. The autoimmune attack generally leads to decreased concentrations of the AChR and damage to the structure of the endplate itself. This information has guided the empiric treatment of patients with MG and has suggested new treatment strategies. Whereas the outcome of patients with MG has improved because of more effective symptomatic treatment, including advances in critical care medicine and the use of cholinesterase inhibitors, the greatest advances have come from therapies that directly reduce the autoimmune attack or modify its effects on the AChR and the surrounding endplate. Immune-directed treatment of patients with MG, which is guided by this information and by data from the management of other autoimmune disease, is aimed at inducing an immunologic remission and then maintaining that remission. Remission induction is usually accomplished through the use of high-dose corticosteroids, frequently in conjunction with IV immunoglobulin or plasmapheresis. Maintenance of the remission is usually accomplished by slow tapering of the corticosteroids along with the use of “steroid-sparing” agents, which include azathioprine, thymectomy, and possibly mycophenolate. Therapy usually begins with cholinesterase inhibitors. If necessary, immune-directed treatment is added, beginning with either thymectomy or high-dose corticosteroids. The short-term therapies, i.e., IV immunoglobulin or plasmapheresis, may be effective in the early stages of treatment or later during an exacerbation. Steroid-sparing medications are usually added to facilitate the tapering phase.
- 1 September 2003
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 998 (1) , 457-472
Treatment Principles in the Management of Autoimmune Myasthenia Gravis
The pathogenesis of myasthenia gravis (MG) involves a T cell-directed antibody-mediated autoimmune attack on the nicotinic acetylcholine receptor (AChR) or, occasionally, on other postsynaptic antigens. The antibodies induce their effects through complement-mediated destruction of the postsynaptic endplate membrane with resultant reduction in endplate AChR, and to a lesser degree by increased turnover of endplate AChR or blockade of AChR function. Considerable progress in the treatment of MG has accrued from so-called symptomatic treatments, including improved critical care of seriously ill patients and medications (e.g., cholinesterase inhibitors) increasing the concentration of acetylcholine at the remaining endplate AChRs. Information from other autoimmune diseases and from the response of the normal immune system to invading pathogens supports the view that the course of MG is characterized by exacerbations and remissions. Therefore, the goal in MG treatment is to induce and maintain a remission. This usually involves combinations of short-term and long-term immunosuppressive agents. Selection of the particular combinations of agents in a given patient is guided by the goal of minimizing the cost/benefit ratio of the regimen in an individual patient. In general, the plan involves an initial forceful attack followed by a slow and measured withdrawal.
- 1 September 2003
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 998 (1) , 457-472
Treatment Principles in the Management of Autoimmune Myasthenia Gravis
The pathogenesis of myasthenia gravis (MG) involves a T cell-directed antibody-mediated autoimmune attack on the nicotinic acetylcholine receptor (AChR) or, occasionally, on other postsynaptic antigens. The antibodies induce their effects through complement-mediated destruction of the postsynaptic endplate membrane with resultant reduction in endplate AChR, and to a lesser degree by increased turnover of endplate AChR or blockade of AChR function. Considerable progress in the treatment of MG has accrued from so-called symptomatic treatments, including improved critical care of seriously ill patients and medications (e.g., cholinesterase inhibitors) increasing the concentration of acetylcholine at the remaining endplate AChRs. Information from other autoimmune diseases and from the response of the normal immune system to invading pathogens supports the view that the course of MG is characterized by exacerbations and remissions. Therefore, the goal in MG treatment is to induce and maintain a remission. This usually involves combinations of short-term and long-term immunosuppressive agents. Selection of the particular combinations of agents in a given patient is guided by the goal of minimizing the cost/benefit ratio of the regimen in an individual patient. In general, the plan involves an initial forceful attack followed by a slow and measured withdrawal.
- 1 May 1994
- Published by Elsevier in Neurologic Clinics
- Vol. 12 (2) , 273-284
Acquired Myasthenia Gravis: Immunopathology
- 1 May 1994
- Published by Elsevier in Neurologic Clinics
- Vol. 12 (2) , 273-284
Acquired Myasthenia Gravis: Immunopathology